Clinical Trial Update: Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI [EARLY_Phase 1]

View source ↗

Summary

An early-phase clinical trial evaluating diagnosis of metastatic tumors using 68Ga-FAPI PET-CT and radioligand therapy with 177Lu-EB-FAPI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• 177Lu-EB-FAPI (Lutetium-177 labeled EB-FAPI)
• 68Ga-FAPI (gallium-68 labeled fibroblast activation protein inhibitor)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: 177Lu-EB-FAPI | EARLY_Phase 1 | Status: RECRUITING